Finds that smoking affects IL-33/ST2 signaling, which may influence cognitive function in schizophrenia patients, indicating new treatment paths.
We found a positive correlation between serum levels of interleukin-33 (IL-33) and the Montreal Cognitive Assessment (MoCA) score in patients with stable schizophrenia, as well as with specific sub-scores. Smoking appears to decrease serum levels of soluble IL-33 receptor, a suppressor of tumorigenicity (sST2), possibly resulting in IL-33’s indirect preservation of cognitive functioning.
No takes yet. Share an insight, caveat, or question.
Janicijevic et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: